Table 3.
Clinical outcomes of AMR patients treated with belatacept plus bortezomib
| Renal Function (sCr, eGFR) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | B/B start | Post-B/B nadir | Most recent (months post-Tx) | Biopsy Day post-Tx | Total IVIG doses | Total PP doses | Total Btz doses (start day) | Bela start Day post-Tx | DSA (Adays to loss) | Days to GL | Urine P/C Ratio (most recent) |
| 1 | 6.1, 10 | 1.2, 101 | 1.2, 101 (30 m) | 20, C4d+ | 7 | 12 | 3 (24) | 21 | A68 (21) B37 (23) DP3 (285) DQ5 (10) |
NA | 0.10 |
| 2 | 3.14, 15 | 0.79, 62 | 1.3, 43 (29 m) | 11, C4d+ | 2 | 4 | 2 (14) | 19 | A3 (6) DP1(22) DP3 (273) |
NA | 0.35 |
| 3 | 2.5, 24 | 0.8, 64 | 1.2, 56 (22 m) | None | 4 | 6 | 4 (32) | 32 | B8 (9) B51 (339) C1(622) DR53(63) |
NA | 0.49 |
| 4 1st episode |
2.1, 45 | 1.31, 98 | NA | 11, C4d+ | 1 | 2 | 4 (18) | 17 | DR7 (5) DR53 (110) DQ2 (320) DQ6 (15) |
NA | NA |
| 4 2nd episode |
1.3, 98 | 1.2, 118 | 1.3, 98 (18 m) | 82, C4d+ | 2 | 2 | 4 (115) | ongoing | DR7 (119) | NA | 0.07 |
| 5 | 8.7, 5 | 3.44, 14 | BHDD (10 m) | 6, C4d+ | 3 | 6 | 2 (9) | 14 | DQ7 (7) DRB1*04 (29) DRB1*14 (3) DR52 (3) |
96 | 4.92 |
| 6 | 2.3, 33 | 1.8, 65 | 1.8, 44 (26 m) | 291, C4d+ | 3 | 4 | 4 (292) | 292 | A1 (9) B8 (9) B44 (9) DQ2 (491) |
NA | 0.16 |
A
days to loss: calculated from day of detection to day of loss;
B
HHD: Hemodialysis